PFE vs VRTV: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Veritiv Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-19.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
Veritiv Corporation · Industrials
$169.99
-45.0% upside to fair value
Med Conviction
Grade D
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
VRTV |
| Current Price |
$27.64 |
$169.99 |
| Fair Value Estimate |
$30.94 |
$93.49 |
| Upside to Fair Value |
+12.0%
|
-45.0%
|
| Market Cap |
$157.5B |
$2.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
5.4x
|
| Price / Sales |
2.5x
|
0.4x
|
| Price / FCF |
14.3x
|
10.4x
|
| Revenue Growth YoY |
+2.6%
|
-19.0%
|
| Gross Margin |
71.3%
|
22.7%
|
| Operating Margin |
25.1%
|
5.9%
|
| Return on Equity |
4.9%
|
48.6%
|
| Dividend Yield |
6.22% |
1.48% |
| FCF Yield |
6.97%
|
9.57%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Veritiv Corporation is a business-to-business distributor of specialty packaging, facility solutions, print, and publishing products, operating through four segments with a network of distribution centers and roughly 5,000 employees. The business quality is mixed: it generates a strong 48.6% ROE and trades at a low 7.13 trailing P/E and 5.44 EV/EBITDA, but revenue declined 19.0% year over year in…
Accumulation Zones
| Metric |
PFE |
VRTV |
| Zone Low |
$23.21 |
$70.12 |
| Zone High |
$26.30 |
$79.47 |
| In Buy Zone? |
No
|
No
|